EHA 2023 | QuANTUM-First: the benefit of quizartinib based on pre-transplant MRD status
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, comments on some of the results from QuANTUM-First (NCT02668653) evaluating the addition of quizartinib in induction and consolidation in patients with FLT3-ITD+ acute myeloid leukemia (AML). Dr Levis explains that, as showed in the MORPHO study (NCT02997202), patients who were measurable residual disease (MRD) negative prior to transplant benefited less from the addition of quizartinib post-transplant. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
